VANCOUVER and SAN DIEGO, Jul 24, 2008 (Canada NewsWire via COMTEX) ----MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious diseases, advises that the directors of MIGENIX Inc. have called a general meeting of shareholders (the "Meeting") to be held at 2:00 p.m. (Vancouver time) on October 31, 2008, at 102 - 2389 Health Sciences Mall, Vancouver, British Columbia. Further details with respect to the Meeting will be provided in an Information Circular to be prepared by MIGENIX and sent to shareholders, together with a Form of Proxy, Notice of Meeting and other relevant Meeting documentation.

About MIGENIX

MIGENIX is committed to advancing therapy, improving health, and enriching life by developing and commercializing drugs primarily in the area of infectious diseases. The Company's programs include drug candidates for: the prevention of catheter-related infections (Phase III), the treatment of dermatological diseases (end of Phase II), the treatment of chronic hepatitis C infections (Phase II and preclinical), the treatment of serious gram positive bacterial infections (preclinical) and the treatment of hepatitis B infections (preclinical). MIGENIX is headquartered in Vancouver, British Columbia, Canada with US operations in San Diego, California. Additional information can be found at www.migenix.com.

"Jim DeMesa"

James M. DeMesa, M.D.

President & CEO

SOURCE: MIGENIX Inc.

Art Ayres, MIGENIX Inc., Tel: (604) 221-9666 Ext. 233, aayres@migenix.com;
   Dian Griesel, Ph.D., Investor Relations Group, Tel: (212) 825-3210, Theproteam@aol.com